INFORMAZIONI SU QUESTO PODCAST 🔗

Durata media dell'audio:
6 minutes
Inglese
Stati Uniti
28 episodi
da 11 Febbraio 2015
episodic

ULTIMO EPISODIO 🔗

Dr Symonds (University Hospital of Leicester, Leicester, UK) talks to ecancertv at ESMO 2014 about his work looking at the use of experimental, drug cediranib, in the treatment of cervical cancer.

CERCA TRA GLI EPISODI PASSATI

Cerca gli episodi passati di ESMO 2014.

EPISODI PRECEDENTI

ecancer's Gordon McVie talks to Anastassia Negrouk, of the European Organisation for Research and Treatment of Cancer (EORTC), at ESMO 2014 on managing data in clinical trials and encouraging more personalised medicine to take place for the progression of cancer care.
Prof Lefebvre (Northern France Comprehensive Cancer Centre, Lille, France) talks to ecancertv at ESMO 2014 about the Make Sense campaign, and the ways in which they are raising the public's awareness of head and neck cancer.
Dr Swain (Washington Cancer Institute, Washington, USA) talks to ecancertv at ESMO 2014 about the results of the CLEOPATRA trial, which demonstrated significant survival benefits for patients with HER2 breast cancer when treated with a combination of pertuzumab, trastuzumab and chemotherapy.
Prof Meunier, Director General of the European Organisation for Research and Treatment of Cancer, Belgium (EORTC) talks to ecancertv at ESMO 2014 about the financial impacts of cancer and the quality of life issues associated with them.
Dr Tahara (National Cancer Center Hospital East, Kashiwa, Japan) talks to ecancertv at ESMO 2014 about the development of a new targeted therapy for the treatment of iodine-refractory thyroid cancer.
Dr Minig (Valencia Institute of Oncology, Valencia, Spain) talks to ecancertv at ESMO 2014 about the need to establish a more standardised world-wide protocol for the treatment of advanced stage ovarian cancer with a focus on a multidisciplinary and specialised approach to surgery which would impro…
Dr Jean-Pascal Machiels of Cliniques Universitaires Saint-Luc, Brussels, Belgium talks to ecancertv at ESMO 2014 in Madrid Spain. He presents results from a phase III trial on the tyrosine kinase inhibitor, afatinib and the significant improvements it has shown in progression-free survival for pati…
Dr Weber (Moffitt Cancer Center, Tampa, USA) talks to ecancertv at ESMO 2014 about the results of a phase III trial which indicated that monoclonal antibody, nivolumab, achieves superior response rates and a longer duration of response than standard chemotherapy in patients whose melanoma has progr…
Dr Gligorov (Assistance Publique Hôpitaux de Paris, Paris, France) talks to ecancertv at ESMO 2014 about his open-label randomised phase III IMELDA trial on metastatic breast cancer. He studied whether the addition of capecitabine to maintenance bevacizumab - continued until disease progression af…
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da ecancer, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.